PUBLISHER: Grand View Research | PRODUCT CODE: 1813790
PUBLISHER: Grand View Research | PRODUCT CODE: 1813790
The China small molecule CDMO market size was estimated at USD 3.71 billion in 2024 and is projected to reach USD 8.34 billion by 2033, growing at a CAGR of 9.58% from 2025 to 2033 The market is driven by rising drug discovery efforts in fields such as oncology, cardiovascular, and central nervous system, leading many pharmaceutical companies to outsource.
Besides, the small molecule CDMOs in China are characterized by favorable cost structures, a skilled workforce, and a growing range of domestic projects, further becoming appealing partners for both local and international companies. In addition, the market's expansion is fueled by the rising demand for generics and innovative small molecule therapies, further propelling the trend toward integrated, end-to-end development and manufacturing solutions. In addition, growing technological advancements in the market have played a crucial role in enhancing the capabilities of China's CDMO sector, which further supports market growth.
Besides, innovations such as process optimization, real-time monitoring via Process Analytical Technology (PAT), and machine learning applications for predictive analytics are increasingly prioritized to improve efficiency and product quality. Moreover, the integration of continuous manufacturing technologies and advanced synthetic chemistry further supports the development of high-potency and complex molecules. This technological advancement has further supported the Chinese CDMOs to compete more effectively in the global arena, particularly for early-phase and high-value niche projects.
China Small Molecule CDMO Market Report Segmentation
This report forecasts revenue growth at a country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the China small molecule CDMO market report based on product, drug, and application.